|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (5Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
The big shareholder groups in TapImmune Inc (NASDAQ:TPIV) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own aRead More...
After ending almost flat in the week ended Sept. 14, biotech stocks have seen some bounce in the running week, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) up about 1.3 percent through Thursday. ...
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Both Innovate Biopharmaceuticals and TapImmune sprang to life on Friday seeing big gains after the companies announced plans to present at conferences this ...
Furthermore, many of the smaller biotechnology stocks have been garnering more interest for novel therapies and even more interest from some of their larger cohorts. A multi-million dollar strategic investment into one of the biotech companies this week has continued to emphasize the focus on the potential that smaller cap biotech companies hold. GT Biopharma (GTBP) for example is generating novel immuno-oncology biopharmaceutical drugs targeting cancers.
Stock Research Monitor: TPIV, VCEL, and VRTX LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration . On Tuesday, July 24, ...
TapImmune (TPIV) stock saw an ~84.1% hike during the week of June 1–8. On June 8, it closed at $9, which was a 249% growth from its 52-week low of $2.58 on April 23. On June 5 and June 6, TPIV stock had consistent growth of ~11.3% and ~11.2%, respectively. On June 8, TapImmune entered into security purchase agreements with some institutional and accredited investors related to the private placement of its equity securities.
Remote patient monitoring, through smaller cheaper technology, is transforming medical care in the U.S. Cardiac care is a major beneficiary, and now major government agencies are signalling that this sector could be a top priority in the coming years. New medical device from Biotricity (BTCY) could shake up a handful of existing companies in cardiac remote monitoring, as their new device has some clear improvements over older technology. With revenue and new product announcements this year, BTCY could move significantly higher in 2018 and 2019.
NEW YORK, NY / ACCESSWIRE / June 11, 2018 / TapImmune and Intercept Pharmaceuticals were two biotech stocks heading higher in Friday trading. Intercept didn't have any particularly remarkable news but did announce that management would be presenting this Tuesday at the Goldman Sachs 39th Annual Global Healthcare Conference.
TapImmune recently announced a merger agreement and reorganization with privately held Marker Therapeutics. The company then announced the formation of a Scientific Advisory Board after the close of the proposed merger May 16.
Stock Monitor: TapImmune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on GTx, Inc. (NASDAQ: GTXI ). If you want access ...
NEW YORK, NY / ACCESSWIRE / March 28, 2018 / TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that ...